Subtopic Deep Dive

Topoisomerases Genomic Stability
Research Guide

What is Topoisomerases Genomic Stability?

Topoisomerases genomic stability examines the enzymes that resolve DNA topology to prevent tangling, replication stress, and chromosomal aberrations during cell division, with dysfunction driving carcinogenesis and therapy-induced malignancies.

Topoisomerases include type IB (TOP1, TOP1MT), type IIA (TOP2A, TOP2B), and type IA (TOP3A, TOP3B) enzymes essential for genome integrity (Pommier et al., 2022, 411 citations). Their inhibition by chemotherapeutics like doxorubicin and cisplatin causes DNA damage but risks secondary cancers via genomic instability. Over 10 key papers from 2010-2022 highlight roles in drug resistance and DNA damage response.

Curated Papers

Key Challenges

Why It Matters

Topoisomerase inhibitors like doxorubicin induce histone eviction from chromatin, enhancing chemotherapeutic efficacy but risking long-term genomic instability (Pang et al., 2013, 422 citations). Dysfunction contributes to cisplatin resistance through systems biology pathways (Galluzzi et al., 2014, 757 citations). Understanding these mechanisms guides safer cancer therapies and predicts radioresistance (Huang and Zhou, 2020, 1065 citations), informing multidrug resistance strategies (Zahreddine and Borden, 2013, 650 citations).

Key Research Challenges

Topoisomerase Poisoning Fork Breakage

Genotoxic treatments poison topoisomerases, leading to replication fork reversal and breakage unless protected by Rad51 (Zellweger et al., 2015, 672 citations). This causes chromosomal aberrations in cancer cells. Balancing therapy efficacy with genomic stability remains unresolved.

Drug Resistance via Heterogeneity

Tumor heterogeneity evolves polyclonal resistance to topoisomerase inhibitors like cisplatin (Burrell and Swanton, 2014, 410 citations). Cells adapt via DNA damage response alterations (Podhorecka et al., 2010, 596 citations). Predicting resistance patterns challenges personalized therapy.

Secondary Malignancy Risk

Therapy-induced topoisomerase dysfunction triggers H2AX phosphorylation and persistent DSBs, risking secondary cancers (Podhorecka et al., 2010, 596 citations). Long-term genomic instability from doxorubicin histone eviction complicates risk assessment (Pang et al., 2013, 422 citations).

Essential Papers

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Edgar Pérez‐Herrero, Alberto Fernández‐Medarde · 2015 · European Journal of Pharmaceutics and Biopharmaceutics · 1.8K citations

DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer

Ruixue Huang, Ping‐Kun Zhou · 2020 · Signal Transduction and Targeted Therapy · 1.1K citations

Abstract Radiotherapy is one of the most common countermeasures for treating a wide range of tumors. However, the radioresistance of cancer cells is still a major limitation for radiotherapy applic...

Systems biology of cisplatin resistance: past, present and future

Lorenzo Galluzzi, Ilio Vitale, Judith Michels et al. · 2014 · Cell Death and Disease · 757 citations

Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells

Ralph Zellweger, Damian Dalcher, Karun Mutreja et al. · 2015 · The Journal of Cell Biology · 672 citations

Replication fork reversal protects forks from breakage after poisoning of Topoisomerase 1. We here investigated fork progression and chromosomal breakage in human cells in response to a panel of su...

Mechanisms and insights into drug resistance in cancer

Hiba Zahreddine, Katherine L. B. Borden · 2013 · Frontiers in Pharmacology · 650 citations

Cancer drug resistance continues to be a major impediment in medical oncology. Clinically, resistance can arise prior to or as a result of cancer therapy. In this review, we discuss different mecha...

H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy

Monika Podhorecka, Andrzej Składanowski, Przemyslaw Bozko · 2010 · Journal of Nucleic Acids · 596 citations

Double‐strand breaks (DSBs) are the most deleterious DNA lesions, which, if left unrepaired, may have severe consequences for cell survival, as they lead to chromosome aberrations, genomic instabil...

Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches

Talha Bin Emran, Asif Shahriar, Aar Rafi Mahmud et al. · 2022 · Frontiers in Oncology · 488 citations

Cancer is one of the leading causes of death worldwide. Several treatments are available for cancer treatment, but many treatment methods are ineffective against multidrug-resistant cancer. Multidr...

Reading Guide

Foundational Papers

Start with Galluzzi et al. (2014, 757 citations) for cisplatin resistance systems biology, Zahreddine and Borden (2013, 650 citations) for drug resistance mechanisms, and Podhorecka et al. (2010, 596 citations) for H2AX in DNA damage response.

Recent Advances

Study Pommier et al. (2022, 411 citations) for comprehensive topoisomerase roles, Huang and Zhou (2020, 1065 citations) for radiotherapy sensitization, and Emran et al. (2022, 488 citations) for MDR approaches.

Core Methods

Core techniques: DNA fiber combing for fork reversal (Zellweger et al., 2015), histone eviction assays for doxorubicin (Pang et al., 2013), and phosphorylation signaling for DSB repair (Podhorecka et al., 2010).

How PapersFlow Helps You Research Topoisomerases Genomic Stability

Discover & Search

Research Agent uses searchPapers and citationGraph to map topoisomerase literature from Pommier et al. (2022, 411 citations), revealing connections to DNA damage response; exaSearch uncovers related works on fork reversal (Zellweger et al., 2015); findSimilarPapers expands to resistance mechanisms.

Analyze & Verify

Analysis Agent applies readPaperContent to extract TOP2A inhibition data from Huang and Zhou (2020), verifies claims with CoVe against Galluzzi et al. (2014), and runs PythonAnalysis for survival curve statistics from doxorubicin studies; GRADE scores evidence on genomic stability impacts.

Synthesize & Write

Synthesis Agent detects gaps in topoisomerase-drug resistance links, flags contradictions between Pommier et al. (2022) and Zahreddine and Borden (2013); Writing Agent uses latexEditText, latexSyncCitations for Pommier et al., and latexCompile for review drafts; exportMermaid visualizes fork reversal pathways.

Use Cases

"Analyze replication fork reversal statistics in topoisomerase poisoning from Zellweger 2015."

Research Agent → searchPapers(Zellweger) → Analysis Agent → readPaperContent → runPythonAnalysis(NumPy plot fork progression data) → matplotlib survival curves output.

"Draft LaTeX review on topoisomerase roles in genomic stability citing Pommier 2022."

Synthesis Agent → gap detection → Writing Agent → latexEditText(intro section) → latexSyncCitations(Pommier, Galluzzi) → latexCompile → PDF with diagrams.

"Find GitHub code for modeling topoisomerase inhibitor resistance."

Research Agent → paperExtractUrls(cisplatin papers) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for resistance simulations.

Automated Workflows

Deep Research workflow systematically reviews 50+ papers on topoisomerase stability: searchPapers → citationGraph(Pommier et al.) → DeepScan(7-step analysis with CoVe checkpoints on fork breakage). Theorizer generates hypotheses on TOP2A in secondary malignancies from Galluzzi et al. (2014) data chains. DeepScan verifies doxorubicin histone eviction claims (Pang et al., 2013).

Try Doxa for Topoisomerases Genomic Stability Research

Frequently Asked Questions

What defines topoisomerases genomic stability?

Topoisomerases resolve DNA supercoils to maintain genomic integrity during replication, with six human enzymes (TOP1, TOP1MT, TOP2A, TOP2B, TOP3A, TOP3B) preventing tangles and aberrations (Pommier et al., 2022).

What are key methods studying topoisomerase dysfunction?

Methods include replication fork tracking via DNA combing (Zellweger et al., 2015), H2AX phosphorylation assays for DSBs (Podhorecka et al., 2010), and systems biology modeling of cisplatin resistance (Galluzzi et al., 2014).

What are landmark papers?

Pommier et al. (2022, 411 citations) reviews all human topoisomerases in stability; Galluzzi et al. (2014, 757 citations) maps cisplatin resistance; Zellweger et al. (2015, 672 citations) shows Rad51 fork reversal post-poisoning.

What open problems exist?

Challenges include predicting polyclonal resistance evolution (Burrell and Swanton, 2014), mitigating therapy-induced secondary malignancies from persistent DSBs (Podhorecka et al., 2010), and balancing inhibitor efficacy with genomic risks.